Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Trogerstrasse 30, 81675 Munich, Germany.
Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Trogerstrasse 30, 81675 Munich, Germany; German Center for Infection Research (DZIF), Munich Partner Site, 81675 Munich, Germany.
Curr Opin Virol. 2017 Jun;24:38-45. doi: 10.1016/j.coviro.2017.03.019. Epub 2017 Apr 20.
Hepatitis B virus (HBV) infection is a global health threat with 240 million chronic carriers at high risk to develop hepatocellular carcinoma. Current antiviral treatment can efficiently control viral replication and reduce liver inflammation, but is still quite far from achieving a cure. Significant progress has been made in understanding the virus life cycle and virus-host interaction in the past few years. With identification of the HBV receptor, cell-culture infection systems have become available that allow drug screening and establishing a pipeline of potential antivirals targeting either viral or host factors. Most of the candidate antivirals summarized in this review are still in preclinical development, but some have already entered or are about to enter early clinical trials.
乙型肝炎病毒（HBV）感染是一个全球性的健康威胁，全球有 2.4 亿慢性携带者面临发展为肝细胞癌的高风险。目前的抗病毒治疗可以有效地控制病毒复制和减少肝脏炎症，但距离治愈还有很长的路要走。在过去的几年中，人们对病毒生命周期和病毒-宿主相互作用有了更深入的了解。随着乙型肝炎病毒受体的鉴定，细胞培养感染系统已经可用，这使得药物筛选和建立针对病毒或宿主因素的潜在抗病毒药物的管道成为可能。本综述中总结的大多数候选抗病毒药物仍处于临床前开发阶段，但有些已经进入或即将进入早期临床试验。
